Genetics of Sorafenib in Liver Cancer Patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether the way your body processes the drug sorafenib (used for liver cancer) affects its safety and effectiveness. It aims to find the best dose for patients based on their genetics, which could lead to better treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of hepatocellular carcinoma (HCC), a type of liver cancer.
- You must not have ever been treated with a TKI drug (like sorafenib or lenvatinib) for your cancer.
- Your liver function should be at Child-Pugh grade A or B (not grade C).
- You should not have any other types of cancer, serious heart/lung/kidney problems, or uncontrolled inflammatory conditions.
- You must be able to take sorafenib without serious allergy or intolerance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This study looks at how your genes and alcohol use together affect the risk of liver cancer. It may help find ways to prevent cancer in people with fatty liver disease or moderate alcohol intake.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.